These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 15626889)

  • 1. CDP571, a humanized anti-tumor necrosis factor-alpha monoclonal antibody in pediatric Crohn's disease.
    Mamula P; Cohen SA; Ferry GD; Kirschner BS; Winter HS; Innes A; Patel J; Baldassano RN;
    Inflamm Bowel Dis; 2004 Nov; 10(6):723-30. PubMed ID: 15626889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease.
    Feagan BG; Sandborn WJ; Baker JP; Cominelli F; Sutherland LR; Elson CO; Salzberg BA; Archambault A; Bernstein CN; Lichtenstein GR; Heath PK; Cameron S; Hanauer SB
    Aliment Pharmacol Ther; 2005 Feb; 21(4):373-84. PubMed ID: 15709987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial.
    Sandborn WJ; Feagan BG; Radford-Smith G; Kovacs A; Enns R; Innes A; Patel J
    Gut; 2004 Oct; 53(10):1485-93. PubMed ID: 15361500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial.
    Feagan BG; Sandborn WJ; Lichtenstein G; Radford-Smith G; Patel J; Innes A
    Aliment Pharmacol Ther; 2006 Mar; 23(5):617-28. PubMed ID: 16480401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial.
    Sandborn WJ; Feagan BG; Hanauer SB; Present DH; Sutherland LR; Kamm MA; Wolf DC; Baker JP; Hawkey C; Archambault A; Bernstein CN; Novak C; Heath PK; Targan SR;
    Gastroenterology; 2001 May; 120(6):1330-8. PubMed ID: 11313302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderate-to-severe Crohn's disease.
    Kierkus J; Dadalski M; Szymanska E; Oracz G; Wegner A; Gorczewska M; Szymanska S; Woynarowski M; Ryzko J
    Eur J Gastroenterol Hepatol; 2012 May; 24(5):495-500. PubMed ID: 22387887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease.
    Baldassano R; Braegger CP; Escher JC; DeWoody K; Hendricks DF; Keenan GF; Winter HS
    Am J Gastroenterol; 2003 Apr; 98(4):833-8. PubMed ID: 12738464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease.
    Kugathasan S; Werlin SL; Martinez A; Rivera MT; Heikenen JB; Binion DG
    Am J Gastroenterol; 2000 Nov; 95(11):3189-94. PubMed ID: 11095340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease.
    Stack WA; Mann SD; Roy AJ; Heath P; Sopwith M; Freeman J; Holmes G; Long R; Forbes A; Kamm MA
    Lancet; 1997 Feb; 349(9051):521-4. PubMed ID: 9048788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of infliximab in the treatment of Crohn's disease in children and adolescents.
    Hyams JS; Markowitz J; Wyllie R
    J Pediatr; 2000 Aug; 137(2):192-6. PubMed ID: 10931411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study.
    Ferrante M; Feagan BG; Panés J; Baert F; Louis E; Dewit O; Kaser A; Duan WR; Pang Y; Lee WJ; Gustafson D; Liao X; Wallace K; Kalabic J; D'Haens GR
    J Crohns Colitis; 2021 Dec; 15(12):2001-2010. PubMed ID: 34077509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.
    Fasanmade AA; Adedokun OJ; Blank M; Zhou H; Davis HM
    Clin Ther; 2011 Jul; 33(7):946-64. PubMed ID: 21741088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adalimumab in patients with Crohn's disease--safety and efficacy in an open-label single centre study.
    Seiderer J; Brand S; Dambacher J; Pfennig S; Jürgens M; Göke B; Ochsenkühn T
    Aliment Pharmacol Ther; 2007 Apr; 25(7):787-96. PubMed ID: 17373917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TNF-alpha antagonists for the treatment of Crohn's disease.
    Kam LY; Targan SR
    Expert Opin Pharmacother; 2000 May; 1(4):615-22. PubMed ID: 11249506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concomitant therapy with methotrexate and anti-TNF-α in pediatric patients with refractory crohn's colitis: a case series.
    Absah I; Faubion WA
    Inflamm Bowel Dis; 2012 Aug; 18(8):1488-92. PubMed ID: 21882301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial.
    Hinojosa J; Gomollón F; García S; Bastida G; Cabriada JL; Saro C; Ceballos D; Peñate M; Gassull MA;
    Aliment Pharmacol Ther; 2007 Feb; 25(4):409-18. PubMed ID: 17269996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of Crohn's disease with anti TNF alpha antibodies--the experience in the Tel Aviv Medical Center].
    Dotan I; Yeshurun D; Hallak A; Horowitz N; Tiomny E; Reif S; Halpern Z; Rachmilewitz D
    Harefuah; 2001 Apr; 140(4):289-93, 368. PubMed ID: 11303390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-TNF therapy for Crohn's disease: a perspective (infliximab is not the drug we have been waiting for).
    Shanahan F
    Inflamm Bowel Dis; 2000 May; 6(2):137-9. PubMed ID: 10833074
    [No Abstract]   [Full Text] [Related]  

  • 20. CDP571, a humanized antibody to human tumor necrosis factor-alpha: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. CPD571 Sepsis Study Group.
    Dhainaut JF; Vincent JL; Richard C; Lejeune P; Martin C; Fierobe L; Stephens S; Ney UM; Sopwith M
    Crit Care Med; 1995 Sep; 23(9):1461-9. PubMed ID: 7664546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.